

# **Palliative Therapie des kolorektalen Karzinoms – ein Entitätsbericht**

Dr. Frank Strohbach, Berlin

28. März 2009


# MVZ Ärzteforum Seestrassen Berlin




# Palliative Therapie des CRC

- 109 beteiligte Praxen
- 2.870 gemeldete Patienten
- 1.837 dokumentierte Patienten
- 1.645 auswertbare Patienten
- 809 verstorbene Patienten  
(vollständiges follow up)


# Vortherapien (adjuvant)




# Palliative Chemotherapien



# Palliative Chemotherapien – 1st-line




# Palliative Chemotherapien – 2nd-line



# Gesamtüberleben ab Erstdiagnose

Gesamtüberleben ab Erstdiagnose - Patienten

n = 1645 Min = 0.7 Max = 215.5




n = 1.645

42,7 Monate




# Gesamtüberleben ab Therapiebeginn (1st-line)



n = 1.640  
1st-line  
Chemotherapie  
21,7 Monate

# Gesamtüberleben 1st-line



n = 1.640

n = 1.532

21,7 Monate

Kombinationstherapie


n = 108

23,1 Monate

Monotherapie

# Gesamtüberleben 1st-line

Gesamtüberleben (Kaplan-Meyer) nach Prognose für alle Therapien




n = 23,2 Monate  
geringes Risiko  
(EORTC: 15,0 Mo.)

n = 18,8 Monate  
intermediäres Risiko  
(EORTC: 11,0 Mo.)

n = 11,0 Monate  
hohes Risiko  
(EORTC: 6,0 Mo.)

# Gesamtüberleben 1st-line




21,7 Monate alle  
n = 1.640

20,0 Monate  
Irinotecan (n = 846)


23,5 Monate  
Oxaliplatin (n = 639)

23,1 Monate  
Antikörper (n = 733)

# Ansprechen 1st-line (Irinotecan)



# Gesamtüberleben 1st-line (Irinotecan)



20,0 Monate  
alle (n = 846)

28,1 Monate  
FOLFIRI+Cetuximab  
(n = 9)


24,4 Monate  
FOLFIRI+Bevacizumab  
(n = 230)

23,2 Monate  
FOLFIRI (n = 89)


22,3 Monate  
Irinotecan/AIO+Bev.  
(n = 372)

17,0 Monate  
Irinotecan/AIO (n = 317)

# Ansprechen 1st-line (Oxaliplatin)



# Gesamtüberleben 1st-line (Oxaliplatin)



23,5 Monate  
alle (n = 639)

24,9 Monate  
FOLFOX 4 (n = 94)


22,6 Monate  
FOLFOX 4 +  
Bevacizumab (n = 14)

22,3 Monate  
FUFOX (n = 208)

19,0 Monate  
FUFOX+Bev. (n = 12)



# Gesamtüberleben 2nd-line



12,4 Monate  
alle (n = 1.038)


12,8 Monate  
Oxaliplatin (n = 433)

11,5 Monate  
Irinotecan (n = 508)

10,1 Monate  
Irinotecan/Cetuximab  
(n = 242)

# Überleben nach Hauttoxizität

Gesamtüberleben (Kaplan-Meyer) nach Hauttoxizität für alle Therapien



## Cetuximab 2nd-line

Grad 0: 6,0 Mo.

Grad 1: 10,0 Mo.

Grad 2: 14,0 Mo.

Grad 3: 18,3 Mo.

Grad 4: 3,0 Mo.